Not Yet RecruitingNot Applicable

Complete Revascularization Via Inferior Part-sternotomy

260 participantsStarted 2023-05-05

Plain-language summary

To verify the effectiveness and safety of minimally invasive coronary artery bypass grafting for complete revascularization of multivessel coronary artery disease via inferior part-sternotomy, We aim to randomize 260 patients undergoing isolated Coronary artery bypass grafting (CABG) to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG from 9 hospitals in China.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Single vessel disease, double vessel disease, left main artery disease without right coronary artery disease.
✕. Concomitant cardiac surgeries(i.e. valve repair or replacement, Maze surgery, left ventricular repair due to ventricular aneurysm).
✕. Redo CABG.
✕. Emergent CABG.
✕. Left ventricular ejection fraction(EF≤35%).
✕. Severe atherosclerosis of the ascending aorta.
✕. Subjects tend to choose surgical approach (via full median sternotomy/inferior part-sternotomy) .
✕. Malignant tumor or other severe systemic diseases.

What they're measuring

Complete revascularization rate immediately after surgery

Timeframe: Immediately after surgery

Trial details

NCT IDNCT05835167

SponsorChina National Center for Cardiovascular Diseases

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-05-04

View on ClinicalTrials.gov More Complete Revascularization trials